rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
TORRENT PHARMACEUTICALS LTD. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Download announcement < Back
28 Sep 2022
Pursuant to Regulation 30 of SEBI (Listing Obligations &amp; Disclosure Requirements) Regulations, 2015, this is to inform you that: The USFDA inspected our manufacturing facility at Indrad, Gujarat from 19-Sep-22 to 28-Sep-22. At the end of the inspection, we have been issued a &apos;Form 483&apos; with 3 observations. None of these observations were related to data integrity. We will respond to the USFDA within stipulated timeline and work closely with USFDA to address the observations at the earliest. We will keep the stock exchanges informed of any material development relating to the above in the future. Please take the information on record.
View all announcements for TORRENT PHARMACEUTICALS LTD. Source: BSE India

Mutual Fund Selector

Find the fund that is right for you